Mylan NV is set to launch Fulphila (pegfilgrastim-jmbd), the first biosimilar to Amgen Inc.'s Neulasta approved by the US FDA, "in the coming weeks" despite ongoing patent litigation with Amgen.
FDA approved the biosimilar on June 4 after Mylan and its partner Biocon Ltd. overcame regulatory hurdles that have...